•   
  •   

UK News British scientists defend AstraZeneca and Oxford against vaccine claims

21:30  26 november  2020
21:30  26 november  2020 Source:   msn.com

Can shark liver, tree bark and sand help deliver the Covid vaccine?

  Can shark liver, tree bark and sand help deliver the Covid vaccine? The jabs will have to be manufactured at an unprecedented scale and pace, transported to every corner of the globe and, ultimately, injected into arm after arm after arm. © Provided by Daily Mail But the race is only partially run. Questions remain. For example, with the Pfizer jab it¿s not clear exactly what is meant by it being ¿90 per cent effective¿.

The British -Swedish pharmaceutical giant is to run a fresh trial of its candidate vaccine at a lower dosage, which the company earlier claimed had performed better than a full dosage. AstraZeneca - Oxford 's would-be vaccine is vying to be the world's first authorized Covid-19 jab

The Oxford University/ AstraZeneca vaccine is coming under increasing scrutiny, with critics questioning the claim that trials showed it could protect up to 90% of people against coronavirus. On Thursday Sir John Bell, Oxford ’s regius professor of medicine and the UK government’s life sciences

British scientists have defended Oxford University and AstraZeneca after questions were raised about the results of their Covid-19 vaccine trial.

AstraZeneca has said it will most likely carry out a further global clinical trial to assess the efficacy of its vaccine after a surprise result found 90% protection was achieved when people were given a half dose followed by a full dose.

The pharmaceutical giant has acknowledged the finding was as a result of a dosing error, but it did not expect any new trial to hold up regulatory approval in countries including the UK.

Oxford and AstraZeneca’s overall efficacy from two different dosing regimes in a phase three trial was announced last week at a combined figure of 70%.

NOT REAL NEWS: A look at what didn't happen this week

  NOT REAL NEWS: A look at what didn't happen this week A look at false and misleading claims and videos circulating after the presidential election and news about COVID-19 vaccines. None of these are legit, even though they were shared widely on social media. The Associated Press checked them out. Here are the facts: ___ Officials debunk multiple claims of dead people voting in Georgia CLAIM: The identities of deceased Georgia residents Linda Kesler, Deborah Jean Christiansen and James Blalock were used to illegally cast ballots in the 2020 election.THE FACTS: No one voted using the identities of these deceased individuals, according to election officials in their respective counties. The rumors started on Nov.

On Monday, the world heard how the UK's Covid vaccine - from AstraZeneca and Oxford University - was highly effective in advanced trials. That's because different doses of the vaccine were mistakenly used in the trial. Some volunteers were given shots half the planned strength, in error.

Doubts about Oxford 's vaccine were raised this week it emerged just 2,300 people were given the dose AstraZeneca said today it will likely to run an additional global trial to bat off criticisms about its The trial used the meningitis vaccine as a control, which scientists argued would elicit a similar

diagram, text: (PA Graphics) © Provided by PA Media (PA Graphics)

A half dose followed by a full dose was found to be 90% effective, according to a subset of data, but the efficacy was 62% for people given two full doses.

Earlier this week, Moncef Slaoui, the scientific head of the US’s Operation Warp Speed – the programme to supply America with vaccines – told US reporters the half-dose regime was only given to people aged 55 and under.

This could pose problems as scientists across the globe are hoping to find vaccines that work in older people who are most at risk from Covid-19.

Results from an earlier phase two study published in The Lancet medical journal showed the vaccine produced a strong response in all age groups.

Professor Andrew Pollard, director of the Oxford Vaccine Group, told reporters at a UK-based press briefing last week that the 90% effectiveness finding had already met the “necessary statistical evidence as required by regulators”.

Boris Johnson will unveil post-December 2 lockdown 'Tiers' TODAY

  Boris Johnson will unveil post-December 2 lockdown 'Tiers' TODAY In a Commons statement today, Boris Johnson is set to confirm the second national lockdown will end in England on December 2, with a return to the regional approach that was in force before. But the rules will be significantly tougher in key respects, leaving the hospitality industry facing 'catastrophic' restrictions while retail is allowed to continue to prop up the economy.The trade-off sparked anger amid warnings that thousands of businesses could be pushed to the wall by the restrictions, even though the hated 10pm pubs curfew is set to be loosened.

Trials of a Covid-19 vaccine being developed by AstraZeneca and Oxford University will resume after being paused due to a reported side effect in a patient in the UK. "This pause shows we will always put safety first. We will back our scientists to deliver an effective vaccine as soon as safely possible

The Oxford and AstraZeneca teams are hopeful of swift approvals, as many regulators have been "This vaccine ’s efficacy and safety confirm that it will be highly effective against COVID-19 and U.K.-based pharmaceutical giant AstraZeneca and England's University of Oxford announced Monday

He said further evidence will probably be available next month but it is “a highly significant result even with the numbers that we have”.

The 90% efficacy was based on a dosing regime given to 2,741 people. The other regime (two doses) involved 8,895 people.

Neither AstraZeneca nor Oxford disclosed at the briefing that the 90% figure was based on adults aged 55 and under.

It comes as some US scientists have questioned a lack of detail in the results put out last week by AstraZeneca and Oxford.

The New York Times reported that AstraZeneca’s Menelas Pangalos had needed to defend the company’s handling of testing and its public disclosures.

How does the Oxford Covid-19 vaccine compare with others?

  How does the Oxford Covid-19 vaccine compare with others? The vaccine being developed by the University of Oxford is up to 90% effective in preventing coronavirus, according to early data.The vaccine being developed by the University of Oxford is up to 90% effective in preventing coronavirus, according to early data from phase three of the clinical trial.

The British government said the U.K. would be the first country to be given access to a vaccine being developed at Oxford University, should it At the time, AstraZeneca said researchers at the Jenner Institute and Oxford Vaccine Group would know by July whether their vaccine – which began human

British -Swedish drug maker AstraZeneca and the University of Oxford on November 23 said that the The Oxford vaccine uses re-engineered version of Chimpanzee adenovirus vector fused with Sputnik V vaccine claims 91.4 percent efficacy in second interim analysis on day 28 after first dose.

Some experts have also raised questions about the use of two differently designed clinical trials in Britain and Brazil, and pooling analysis from both.

They also say it is unclear how many coronavirus cases were found in each group of the trial.

John Moore, a professor of microbiology and immunology at Weill Cornell Medical College, told the New York Times: “The press release raised more questions than it answered.”

Mr Pangalos said the half-dose finding “could end up being quite a useful mistake”, adding: “What is there to disclose? It actually doesn’t matter whether it was done on purpose or not.”

The Oxford vaccine is only £2 to £3 per dose and can be more easily stored than vaccines from Pfizer/BioNTech and Moderna, which require very cold temperatures.

The jab is being assessed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the UK.

Oxford’s 90% vaccine finding was ‘only in younger age groups’

  Oxford’s 90% vaccine finding was ‘only in younger age groups’ Oxford University scientists have said they are looking closely at the data and are due to publish in a peer-reviewed journal shortly.Moncef Slaoui, the scientific head of the US’s Operation Warp Speed – the programme to supply America with vaccines – told US reporters that the half-dose regime, which was discovered by accident, was only given to younger age groups.

In an interview with the PA news agency last week, Tom Keith-Roach, president of AstraZeneca UK, said there had been “highly statistically significant efficacy results in all subgroups… so I think the regulators will look at it on that basis”.

Helen Fletcher, professor of immunology at London School of Hygiene and Tropical Medicine (LSHTM), said: “What’s remarkable is that Oxford University and AstraZeneca have gone from square one to 100 million doses in less than a year.

“It’s not surprising if some manufacturing issues were still being ironed out when they started clinical trials but early stage trials are all about safety and the safety data we have seen has been very robust.”

She said it was important to wait for the full dataset to be published.

“I also think it’s possible that a lower initial vaccine dose could result in higher vaccine efficacy,” she said.

“More is not necessarily better when it comes to vaccines and immunotherapies. You need to stimulate an immune response but if you push too hard you can get hit a negative feedback loop where the immune system seeks to control and dampen down the response.

“It’s also possible that a strong immune response to the first vaccine could effectively block an immune response to the second shot of the same vaccine – but we should be able to see evidence of that when the data is published.”

Regulator formally asked to assess Oxford University and AstraZeneca vaccine

  Regulator formally asked to assess Oxford University and AstraZeneca vaccine Health Secretary Matt Hancock has said a vaccine could be rolled out from December.The move “marks a significant first step in getting the vaccine approved for deployment” if it meets safety, efficacy and quality standards, the Department of Health and Social Care (DHSC) said.

Stephen Evans, professor of pharmacoepidemiology at LSHTM, said “the idea that no protocol has been published (by Oxford and AstraZeneca) is simply not true”.

He added: “The variety of age groups and dosing regimes is a feature of a number of the vaccine trials and not just the Oxford AstraZeneca vaccine.

“The way the data are put together will have been specified in the protocol and scrutinised very carefully by regulators to ensure that there is no ‘cherry picking’ of the results.”

Joy Leahy of the Royal Statistical Society said the scientific community was “rightly seeking more data in the form of a peer-reviewed paper”, but a press release was put out because of the risk to financial markets from too many people knowing the results while awaiting peer-review publication.

She said the “dosing error does throw up some problems” and the 90% result found may be due to random statistical variation.

“There are also some other complications in looking at this subgroup given that they were all in one location and apparently not representative of the full age profile in the trial,” she added.

Paul Hunter, professor of medicine at the University of East Anglia, told PA: “Given that many vaccines are less effective in older people, we have to be even more cautious about taking this 90% efficacy at face value, at least for older people.”

A spokesman for AstraZeneca told PA on Thursday: “As the development of the vaccine was scaled up into the Oxford-sponsored Phase II/III trial, the measurement used for earlier trials was shown to over-estimate the strength of dose in the new larger batches, resulting in a half dose of the vaccine being administered.

“This was reviewed by the independent Data Safety Monitoring Board and the UK regulator, both of whom approved the continuation of this dosing regimen and the regulator publicly confirmed that there was ‘no concern’.

“All other regulatory authorities were informed that we would continue to monitor and study this cohort. Given the high efficacy we have now seen with the different dosing regimens, there is strong merit in continuing to further investigate these findings in order to establish the most effective dosing regimen.

“We are in discussions with regulators around the world to evaluate these findings and we look forward to the publication of the peer-reviewed results, which has now been submitted to the journal.”

Oxford University said it would not comment ahead of the data appearing in a peer-reviewed publication.

WHO needs 'more than press release' on Oxford jab, says vaccines chief .
The World Health Organisation (WHO) has said it needs "more than a press release" about the Oxford/AstraZeneca vaccine in order to evaluate trial results. © Other Katherine O'Brien said 'more than a press release' was needed from the Oxford/AstraZeneca vaccine trial. Pic: YouTube/WHO Speaking at a WHO news conference on Friday, its immunisations director Dr Katherine O'Brien said: "What we have seen is a press release.

usr: 4
This is interesting!